Onconova Therapeutics, Inc. (ONTX): Price and Financial Metrics

Onconova Therapeutics, Inc. (ONTX)

Today's Latest Price: $0.32 USD

0.00 (0.69%)

Updated Dec 4 4:00pm

Add ONTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 369 in Miscellaneous

See all "A" rated Strong Buy stocks

ONTX Stock Summary

  • For ONTX, its debt to operating expenses ratio is greater than that reported by just 0.51% of US equities we're observing.
  • With a price/sales ratio of 283.77, Onconova Therapeutics Inc has a higher such ratio than 98.43% of stocks in our set.
  • As for revenue growth, note that ONTX's revenue has grown -90.78% over the past 12 months; that beats the revenue growth of just 1.28% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Onconova Therapeutics Inc, a group of peers worth examining would be CLDX, ADAP, ADXS, CANF, and ARCT.
  • ONTX's SEC filings can be seen here. And to visit Onconova Therapeutics Inc's official web site, go to www.onconova.com.

ONTX Stock Price Chart Interactive Chart >

Price chart for ONTX

ONTX Price/Volume Stats

Current price $0.32 52-week high $1.56
Prev. close $0.32 52-week low $0.19
Day low $0.31 Volume 11,181,900
Day high $0.34 Avg. volume 15,489,834
50-day MA $0.28 Dividend yield N/A
200-day MA $0.46 Market Cap 59.66M

ONTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ONTX Latest Social Stream

Loading social stream, please wait...

View Full ONTX Social Stream

Latest ONTX News From Around the Web

Below are the latest news stories about Onconova Therapeutics Inc that investors may wish to consider to help them evaluate ONTX as an investment opportunity.

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2020 Results - Earnings Call Transcript

Onconova Therapeutics, Inc. (ONTX) Q2 2020 Earnings Conference Call Aug 12, 2020 4:30 PM ET Company Participants Avi Oler - Vice President, Corporate Development and General Counsel Steve Fruchtman - President and Chief Executive Officer Mark Guerin - Chief Financial Officer Ric Woodman - Chief Medical Officer and Senior Vice...

SA Transcripts on Seeking Alpha | August 13, 2020

Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …

GlobeNewswire | August 12, 2020

Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12

GlobeNewswire | August 7, 2020

Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020

GlobeNewswire | July 29, 2020

Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020NEWTOWN, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the required number of survival events for the pivotal Phase 3 INSPIRE has been reached. The Company anticipates announcing topline data by the end of the third quarter of 2020. “Consistent with previous guidance for topline data disclosure, we anticipate providing preliminary efficacy and safety data from the pivotal Phase 3 INSPIRE trial during the third quarter of this year,” said Steven M. Fruchtman, M.D., President and Chief Exe...

Yahoo | July 29, 2020

Read More 'ONTX' Stories Here

ONTX Price Returns

1-mo 22.61%
3-mo 49.05%
6-mo -34.31%
1-year -8.57%
3-year -98.56%
5-year -99.84%
YTD -16.45%
2019 -81.85%
2018 -90.62%
2017 -33.92%
2016 -76.35%
2015 -70.82%

Continue Researching ONTX

Want to see what other sources are saying about Onconova Therapeutics Inc's financials and stock price? Try the links below:

Onconova Therapeutics Inc (ONTX) Stock Price | Nasdaq
Onconova Therapeutics Inc (ONTX) Stock Quote, History and News - Yahoo Finance
Onconova Therapeutics Inc (ONTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9284 seconds.